Listed by the USPTO as BASQUILL, SEAN M
Tech Center 1600 • Art Units: 1612 1613 1614
This examiner grants 39% of resolved cases
BASQUILL, SEAN M is a USPTO patent examiner in tech center 1600 and art unit 1612. The profile records 1077 resolved cases, an allowance rate of 38.7%, an interview lift of 21.1%, and a median time to allowance of 1239 days.
The allowance rate exceeds the interview lift, but both figures support careful assessment of claim presentation and response strategy. The listed companies are Ocular Therapeutix Inc., The Regents of the University of Michigan, and AbbVie Inc. The listed firms are MYERS BIGEL, P.A., Brooks Kushman P.C., and CANTOR COLBURN LLP - UPL LIMITED. The large record and named participants provide context for practitioners evaluating this examiner’s prosecution history.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18737473 | ENHANCED PLANT GROWTH VIA PROCESSED PLANT CELL WALL MATERIAL | Non-Final OA | The Regents of the University of Michigan |
| 18685853 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | Final Rejection | The Board of Trustees of the University of Illinois |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | Non-Final OA | Allergan, Inc. |
| 18845312 | AGROCHEMICAL EMULSIFIABLE COMPOSITION | Final Rejection | Nippon Kayaku Kabushiki Kaisha |
| 18535180 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | Non-Final OA | The Johns Hopkins University |
| 17936208 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18832440 | IONIZABLE LIPIDS, LIPID NANOPARTICLES, AND USES THEREOF | Non-Final OA | Verily Life Sciences LLC |
| 17772695 | SUPPOSITORY CAPSULE | Final Rejection | R.P. Scherer Technologies, LLC |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | Non-Final OA | Glaukos Corporation |
| 17788266 | HAIR COSMETIC COMPOSITION | Non-Final OA | KAO CORPORATION |
| 18250114 | NANOPARTICLES FOR IMAGING AND THERAPY | Non-Final OA | University of Connecticut |
| 18839843 | POULTICE AND METHOD FOR MANUFACTURING SAME | Final Rejection | HISAMITSU PHARMACEUTICAL CO., INC. |
| 18840735 | COMPOSITIONS AND METHODS FOR LONG LASTING DISINFECTION WITH MIXED SOLVENT SYSTEMS | Non-Final OA | Specialty Operations France |
| 16969864 | METHODS AND COMPOSITIONS FOR PREVENTING, REDUCING OR ERADICATING TOXICITY CAUSED BY ACETAMINOPHEN (APAP) | Non-Final OA | SINEW PHARMA INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy38.7% of resolved applications examined by Sean M Basquill were allowed (1,077 resolved cases), compared with 40.6% across Art Unit 1612 over the last five years.
This examiner's interview lift is +21.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sean M Basquill took 1,239 days on average from filing to allowance.
Sean M Basquill examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).